Under the terms of the agreement, Aclaris will receive an upfront payment of
“We are very excited to partner ATI-1777 with Pediatrix in
About
About
Pediatrix Therapeutics is a biotechnology company focusing on developing and commercializing high quality, pediatric-friendly and affordable therapeutics and healthcare products to children and families in
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Aclaris’ current beliefs and expectations. These forward-looking statements include Aclaris’ expectations regarding the potential reach and benefits of ATI-1777. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Aclaris’ reliance on third parties over which it may not always have full control, Aclaris’ ability to enter into strategic partnerships on commercially reasonable terms, the uncertainty regarding the COVID-19 pandemic and other risks and uncertainties that are described in the Risk Factors section of Aclaris’ Annual Report on Form 10-K for the year ended
Aclaris Therapeutics Contact:
Vice President, Investor Relations
484-639-7235
rdoody@aclaristx.com
Source: Aclaris Therapeutics, Inc.